| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
1.41(B) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.6 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.3 |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 16.7 |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
17,604 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$160,420 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
3 |
3 |
| Total Shares Sold |
280,916 |
294,129 |
403,559 |
1,047,483 |
| Total Sell Value |
$4,281,159 |
$4,424,082 |
$5,556,813 |
$12,970,668 |
| Total People Sold |
5 |
6 |
6 |
9 |
| Total Sell Transactions |
5 |
7 |
14 |
48 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kilroy Conor |
SVP, GC & Secretary |
• – – |
2021-02-26 |
4 |
AS |
$9.11 |
$63,670 |
D/D |
(6,989) |
122,336 |
|
33% |
|
| Shetzline Michael |
CMO, SVP & Head of Drug Devt. |
• – – |
2021-02-26 |
4 |
AS |
$9.11 |
$40,439 |
D/D |
(4,439) |
160,859 |
|
33% |
|
| Mccourt Thomas A |
President |
• – – |
2021-02-26 |
4 |
AS |
$9.11 |
$133,780 |
D/D |
(14,685) |
471,577 |
|
33% |
|
| Consylman Gina |
SVP, CFO & Treasurer |
• – – |
2021-02-26 |
4 |
AS |
$9.11 |
$167,679 |
D/D |
(18,406) |
336,244 |
|
33% |
|
| Owens Edward P |
Director |
– • – |
2021-02-25 |
4 |
B |
$9.11 |
$45,550 |
D/D |
5,000 |
215,954 |
2.39 |
36% |
|
| Owens Edward P |
Director |
– • – |
2021-02-24 |
4 |
B |
$9.26 |
$64,820 |
D/D |
7,000 |
210,954 |
2.39 |
33% |
|
| Consylman Gina |
SVP, CFO & Treasurer |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
84,951 |
354,650 |
|
- |
|
| Shetzline Michael |
CMO, SVP & Head of Drug Devt. |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
58,252 |
165,298 |
|
- |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
84,951 |
320,333 |
|
- |
|
| Mccourt Thomas A |
President |
• – – |
2021-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
145,631 |
486,262 |
|
- |
|
| Dreyfus Andrew |
Director |
– • – |
2020-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,357 |
113,360 |
|
- |
|
| Denner Alexander J |
Director |
– • – |
2020-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
661 |
37,844 |
|
- |
|
| Mccourt Thomas A |
President |
• – – |
2020-12-14 |
4 |
D |
$12.20 |
$989,286 |
D/D |
(81,089) |
340,631 |
|
- |
|
| Mccourt Thomas A |
President |
• – – |
2020-12-14 |
4 |
OE |
$9.89 |
$988,881 |
D/D |
99,988 |
421,720 |
|
- |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-12-04 |
4 |
AS |
$12.50 |
$70,488 |
D/D |
(5,639) |
93,041 |
|
-11% |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-12-04 |
4 |
OE |
$9.12 |
$51,428 |
D/D |
5,639 |
98,680 |
|
- |
|
| Shepard Jay |
Director |
– • – |
2020-12-03 |
4 |
A |
$0.00 |
$0 |
D/D |
35,557 |
35,557 |
|
- |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-11-11 |
4 |
AS |
$11.75 |
$41,842 |
D/D |
(3,561) |
93,041 |
|
-8% |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-11-11 |
4 |
OE |
$9.31 |
$33,153 |
D/D |
3,561 |
96,602 |
|
- |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-11-09 |
4 |
AS |
$10.92 |
$10,101 |
D/D |
(925) |
93,041 |
|
7% |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2020-11-09 |
4 |
AS |
$10.92 |
$4,302 |
D/D |
(394) |
235,382 |
|
7% |
|
| Kilroy Conor |
SVP, GC & Secretary |
• – – |
2020-11-09 |
4 |
AS |
$10.92 |
$9,129 |
D/D |
(836) |
128,833 |
|
7% |
|
| Consylman Gina |
SVP, CFO & Treasurer |
• – – |
2020-11-09 |
4 |
AS |
$10.92 |
$15,452 |
D/D |
(1,415) |
269,699 |
|
7% |
|
| Denner Alexander J |
Director |
– • – |
2020-11-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
14,040,000 |
|
7% |
|
| Denner Alexander J |
Director |
– • – |
2020-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
37,183 |
37,183 |
|
- |
|
914 Records found
|
|
Page 8 of 37 |
|
|
0.18 (2.17%) 
